A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

Study Summary

The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.

Conditions

Achondroplasia

Interventions / Drugs

Navepegritide Placebo for navepegritide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment24 participants

Primary Completion—

Lead SponsorAscendis Pharma A/S

Data Retrieved2026-04-11 02:54:40.919395+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.